Skip to main content
. Author manuscript; available in PMC: 2018 Aug 15.
Published in final edited form as: Bioorg Med Chem. 2017 Jun 27;25(16):4464–4474. doi: 10.1016/j.bmc.2017.06.035

Figure 8.

Figure 8

Treatment of SKOV-3 human derived ovarian cancer cells with compounds 6 and 7 at four concentration showed enhanced cell growth at the 120 hour time point with 24 hour (constant) drug treatment ( Upper Panel), and reduced growth at the same time point when the “low-dose naltrexone” regimen of pulsed therapy is used (Lower Panels).